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Background
Treatment with ipilimumab improves overall survival
(OS) in patients with metastatic melanoma. Because ipi-
limumab targets T lymphocytes and not the tumor itself,
efficacy may be uniquely sensitive to immunomodula-
tory factors present at the time of treatment.
Methods
We analyzed serum from patients with metastatic mela-
noma (247 of 273, 90.4%) randomly assigned to receive
ipilimumab or gp100 peptide vaccine (NCT00094653). We
quantified candidate biomarkers at baseline and assessed
the association of each with overall survival using univari-
ate and multivariate analyses. Results were confirmed in
an independent cohort of similar patients (48 of 52, 92.3%)
treated with ipilimumab (NCT00495066).
Results
Univariate analysis of biomarkers identified chemokine
(C-X-C motif) ligand 11 (CXCL11) and soluble MHC
class I polypeptide-related chain A (sMICA) as potential
predictive biomarkers for ipilimumab but not gp100
therapy for metastatic melanoma. After controlling for
baseline covariates, elevated CXCL11 and sMICA were
associated with poor OS in ipilimumab-treated patients
(log10 CXCL11: hazard ratio (HR), 1.88; 95% CI, 1.14 to
3.12; P = 0.014; and log10 sMICA quadratic effect P =
0.066; sMICA (≥247 vs < 247): HR, 1.75; 95% CI, 1.02
to 3.01) but not in gp100-treated patients. Multivariate
analysis of an independent ipilimumab-treated cohort
confirmed the association between log10 CXCL11 and
OS (HR, 3.18; 95% CI 1.13 to 8.95; P = 0.029), while
sMICA was less strongly associated with OS (log10
sMICA quadratic effect P = 0.16; sMICA (≥247 vs <
247): HR, 1.48; 95% CI, 0.67 to 3.27).
Conclusion
Low baseline CXCL11 and sMICA were associated with
improved OS in patients with metastatic melanoma
after ipilimumab treatment but not vaccine treatment.
Thus, pretreatment CXCL11 and sMICA may represent
predictors of survival benefit after ipilimumab treatment
as well as therapeutic targets. Furthermore, their role in
recruiting T regulatory cells (CXCL11) and inhibiting
cytolytic effector cells (sMICA) suggests that combina-
tion therapies targeting these molecules may synergize
with CTLA-4 blockade in patients.
Authors’ details
1Earle A. Chiles Research Institute, Portland, OR, USA. 2R&D Systems,
Minneapolis, MN, USA. 3Providence Cancer Center, Portland, OR, USA.
4Providence Portland Medical Center, Portland, OR, USA. 5Bristol-Myers
Squibb, Redwood City, CA, USA. 6Robert W. Franz Cancer Research Center,
Portland, OR, USA.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P96
Cite this article as: Koguchi et al.: Serum immunoregulatory proteins as
predictors of overall survival of metastatic melanoma patients treated
with ipilimumab. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P96.
1Earle A. Chiles Research Institute, Portland, OR, USA
Full list of author information is available at the end of the article
Koguchi et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P96
http://www.immunotherapyofcancer.org/content/3/S2/P96
© 2015 Koguchi et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
